Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Selective activation of blood coagulation in tumor vessels with subsequent tumor infarction is a promising anticancer strategy. To this end, a fusion protein consisting of the extracellular domain of tissue factor [truncated tissue factor (tTF)] was fused to the peptide GRGDSP selectively targeting αv-integrins on tumor endothelial cells. tTF-RGD retained its thrombogenic and integrin-binding activity in vitro. In vivo studies in mice bearing human adenocarcinomas (CCL185), melanoma (M21), and fibrosarcoma (HT1080) revealed that i.v. administration of tTF-RGD induced thrombotic occlusion of tumor vessels resulting in tumor growth retardation or regression in all three types of solid tumors. No apparent side effects, such as thrombosis, in other organs or other treatment-related toxicities were observed. Reduced tumor blood flow in tTF-RGD–treated animals as determined by contrast-enhanced magnetic resonance imaging underlines the proposed mechanism. In conclusion, we consider RGD peptide–directed delivery of tTF as alternative to previously used antibody fusion proteins. Small peptide-directed delivery of coaguligands does not cause immunologic side effects and those caused by accumulation in the reticuloendothelial system. This is the first report to describe the induction of selective thrombosis in tumor vessels by RGD peptide–directed delivery of tTF, which may be a promising strategy for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library.
Koivunen, E., Gay, D. A., & Ruoslahti, E. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80715-7 · Cited by 344
Cited by
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,801
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
The relationship between tissue factor and cancer progression: insights from bench and bedside
van den Berg, Y. W., Osanto, S., Reitsma, P. H., & Versteeg, H. H. (2012) · Blood · doi:10.1182/blood-2011-06-317685 · Cited by 354
Tumor vascular infarction: prospects and challenges
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-016-2171-3 · Cited by 88
Jahanban-Esfahlan, R., Seidi, K., Monhemi, H., Adli, A. D. F., Minofar, B., Zare, P., Farajzadeh, D., Farajnia, S., Behzadi, R., Abbasi, M. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05326-9 · Cited by 58
Metadata
- Authors
- Kessler, T., Bieker, R., Padró, T., Schwöppe, C., Persigehl, T., Bremer, C., Kreuter, M., Berdel, W. E., & Mesters, R. M.
- Venue
- Clinical Cancer Research
- Published
- 2005-09-01
- Volume
- 11
- Issue
- 17
- Pages
- 6317-6324
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2034350111
- Cited by
- 76
- References
- 3
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0389
- The paper
- Kessler, T., Bieker, R., Padró, T., Schwöppe, C., Persigehl, T., Bremer, C., Kreuter, M., Berdel, W. E., & Mesters, R. M. (2005). Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.